{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:09:12Z","timestamp":1787260152025,"version":"build-2736575974"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09152-8","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:10:34Z","timestamp":1774721434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions"],"prefix":"10.1007","volume":"69","author":[{"given":"Juling","family":"Sia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernett","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-3124","authenticated-orcid":false,"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"9152_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40259-025-00706-4","volume":"39","author":"V Solitano","year":"2025","unstructured":"Solitano V, Estevinho MM, Ungaro F et al (2025) TL1A inhibition in inflammatory bowel disease: a pipeline review. BioDrugs 39:171\u2013183. https:\/\/doi.org\/10.1007\/s40259-025-00706-4","journal-title":"BioDrugs"},{"key":"9152_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","volume":"74","author":"G Bamias","year":"2025","unstructured":"Bamias G, Menghini P, Pizarro TT, Cominelli F (2025) Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD. Gut 74:652\u2013668. https:\/\/doi.org\/10.1136\/gutjnl-2024-332504","journal-title":"Gut"},{"key":"9152_CR3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ibd\/izab193","volume":"28","author":"M Hassan-Zahraee","year":"2022","unstructured":"Hassan-Zahraee M, Ye Z, Xi L et al (2022) Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis. Inflamm Bowel Dis 28:434\u2013446. https:\/\/doi.org\/10.1093\/ibd\/izab193","journal-title":"Inflamm Bowel Dis"},{"key":"9152_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891328","volume":"13","author":"W-D Xu","year":"2022","unstructured":"Xu W-D, Li R, Huang A-F (2022) Role of TL1A in inflammatory autoimmune diseases: a comprehensive review. Front Immunol 13:891328. https:\/\/doi.org\/10.3389\/fimmu.2022.891328","journal-title":"Front Immunol"},{"key":"9152_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","volume":"22","author":"S Vieujean","year":"2025","unstructured":"Vieujean S, Jairath V, Peyrin-Biroulet L et al (2025) Understanding the therapeutic toolkit for inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 22:371\u2013394. https:\/\/doi.org\/10.1038\/s41575-024-01035-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9152_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1053\/j.gastro.2008.04.037","volume":"135","author":"H Takedatsu","year":"2008","unstructured":"Takedatsu H, Michelsen KS, Wei B et al (2008) TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135:552\u2013567. https:\/\/doi.org\/10.1053\/j.gastro.2008.04.037","journal-title":"Gastroenterology"},{"key":"9152_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/19420862.2018.1440164","volume":"10","author":"AW Clarke","year":"2018","unstructured":"Clarke AW, Poulton L, Shim D et al (2018) An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. mAbs 10:664\u2013677. https:\/\/doi.org\/10.1080\/19420862.2018.1440164","journal-title":"mAbs"},{"key":"9152_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","volume":"391","author":"BE Sands","year":"2024","unstructured":"Sands BE, Feagan BG, Peyrin-Biroulet L et al (2024) Phase 2 trial of anti-TL1A monoclonal antibody Tulisokibart for ulcerative colitis. N Engl J Med 391:1119\u20131129. https:\/\/doi.org\/10.1056\/NEJMoa2314076","journal-title":"N Engl J Med"},{"key":"9152_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2468-1253(25)00071-8","volume":"10","author":"BG Feagan","year":"2025","unstructured":"Feagan BG, Sands BE, Siegel CA et al (2025) Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn\u2019s disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol 10:715\u2013725. https:\/\/doi.org\/10.1016\/S2468-1253(25)00071-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9152_CR10","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1002\/1873-3468.12747","volume":"591","author":"S Bittner","year":"2017","unstructured":"Bittner S, Ehrenschwender M (2017) Multifaceted death receptor 3 signaling\u2014promoting survival and triggering death. FEBS Lett 591:2543\u20132555. https:\/\/doi.org\/10.1002\/1873-3468.12747","journal-title":"FEBS Lett"},{"key":"9152_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.smim.2014.05.004","volume":"26","author":"MS Hayden","year":"2014","unstructured":"Hayden MS, Ghosh S (2014) Regulation of NF-\u03baB by TNF family cytokines. Semin Immunol 26:253\u2013266. https:\/\/doi.org\/10.1016\/j.smim.2014.05.004","journal-title":"Semin Immunol"},{"key":"9152_CR12","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.3390\/ijms25063228","volume":"25","author":"K Ranjan","year":"2024","unstructured":"Ranjan K, Pathak C (2024) Cellular dynamics of Fas-associated death domain in the regulation of cancer and inflammation. Int J Mol Sci 25:3228. https:\/\/doi.org\/10.3390\/ijms25063228","journal-title":"Int J Mol Sci"},{"key":"9152_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale J, Thomas J, Salvatore M et al (2013) The Genotype-Tissue Expression (GTEx) project. Nat Genet 45:580\u2013585. https:\/\/doi.org\/10.1038\/ng.2653","journal-title":"Nat Genet"},{"key":"9152_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120771120","volume":"120","author":"F Meng","year":"2023","unstructured":"Meng F, Jiang X, Wang X et al (2023) Tumor necrosis factor-like cytokine 1A plays a role in inflammatory bowel disease pathogenesis. Proc Natl Acad Sci U S A 120:e2120771120. https:\/\/doi.org\/10.1073\/pnas.2120771120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9152_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3877617","volume":"2021","author":"Y Luo","year":"2021","unstructured":"Luo Y, Guo J, Jia W et al (2021) TNF-like ligand 1 aberrance aggravates nonalcoholic steatohepatitis via M1 macrophage polarization. Oxid Med Cell Longev 2021:3877617. https:\/\/doi.org\/10.1155\/2021\/3877617","journal-title":"Oxid Med Cell Longev"},{"key":"9152_CR16","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.4049\/jimmunol.179.6.3742","volume":"179","author":"F Tian","year":"2007","unstructured":"Tian F, Grimaldo S, Fugita M et al (2007) The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 179:3742\u20133751. https:\/\/doi.org\/10.4049\/jimmunol.179.6.3742","journal-title":"J Immunol"},{"key":"9152_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cyto.b.21372","volume":"92","author":"TJ Slebioda","year":"2017","unstructured":"Slebioda TJ, Bojarska-Junak A, Cyman M et al (2017) Expression of death receptor 3 on peripheral blood mononuclear cells differes in adult IBD patients and children with newly diagnosed IBD. Cytometry B Clin Cytom 92:165\u2013169. https:\/\/doi.org\/10.1002\/cyto.b.21372","journal-title":"Cytometry B Clin Cytom"},{"key":"9152_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118220","volume":"262","author":"F Han","year":"2020","unstructured":"Han F, Song J, Jia W et al (2020) TL1A primed dendritic cells activation exacerbated chronic murine colitis. Life Sci 262:118220. https:\/\/doi.org\/10.1016\/j.lfs.2020.118220","journal-title":"Life Sci"},{"key":"9152_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/mi.2010.70","volume":"4","author":"VY Taraban","year":"2011","unstructured":"Taraban VY, Slebioda TJ, Willoughby JE et al (2011) Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 4:186\u2013196. https:\/\/doi.org\/10.1038\/mi.2010.70","journal-title":"Mucosal Immunol"},{"key":"9152_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1556\/EuJMI.2.2012.2.1","volume":"2","author":"KR Karlmark","year":"2012","unstructured":"Karlmark KR, Tacke F, Dunay IR (2012) Monocytes in health and disease - minireview. Eur J Microbiol Immunol 2:97\u2013102. https:\/\/doi.org\/10.1556\/EuJMI.2.2012.2.1","journal-title":"Eur J Microbiol Immunol"},{"key":"9152_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1222","volume":"9","author":"G Sreejit","year":"2020","unstructured":"Sreejit G, Fleetwood AJ, Murphy AJ, Nagareddy PR (2020) Origins and diversity of macrophages in health and disease. Clin Transl Immunol 9:e1222. https:\/\/doi.org\/10.1002\/cti2.1222","journal-title":"Clin Transl Immunol"},{"key":"9152_CR22","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.4049\/jimmunol.0903782","volume":"184","author":"JE McLaren","year":"2010","unstructured":"McLaren JE, Calder CJ, McSharry BP et al (2010) The TNF-like protein 1A\u2013death receptor 3 pathway promotes macrophage foam cell formation in vitro. J Immunol 184:5827\u20135834. https:\/\/doi.org\/10.4049\/jimmunol.0903782","journal-title":"J Immunol"},{"key":"9152_CR23","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.2337\/db19-1231","volume":"69","author":"N Maixner","year":"2020","unstructured":"Maixner N, Pecht T, Haim Y et al (2020) A TRAIL-TL1A Paracrine Network Involving Adipocytes, Macrophages, and Lymphocytes Induces Adipose Tissue Dysfunction Downstream of E2F1 in Human Obesity. Diabetes 69:2310\u20132323. https:\/\/doi.org\/10.2337\/db19-1231","journal-title":"Diabetes"},{"key":"9152_CR24","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.3390\/ijms26115017","volume":"26","author":"E Tettoni","year":"2025","unstructured":"Tettoni E, Gabbiadini R, Dal Buono A et al (2025) TL1A as a Target in Inflammatory Bowel Disease: Exploring Mechanisms and Therapeutic Potential. Int J Mol Sci 26:5017. https:\/\/doi.org\/10.3390\/ijms26115017","journal-title":"Int J Mol Sci"},{"key":"9152_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1189\/jlb.3RI0315-095R","volume":"98","author":"AC Richard","year":"2015","unstructured":"Richard AC, Ferdinand JR, Meylan F et al (2015) The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. J Leukoc Biol 98:333\u2013345. https:\/\/doi.org\/10.1189\/jlb.3RI0315-095R","journal-title":"J Leukoc Biol"},{"key":"9152_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/mi.2013.92","volume":"7","author":"X Yu","year":"2014","unstructured":"Yu X, Pappu R, Ramirez-Carrozzi V et al (2014) TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol 7:730\u2013740. https:\/\/doi.org\/10.1038\/mi.2013.92","journal-title":"Mucosal Immunol"},{"key":"9152_CR27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1164\/rccm.201909-1722OC","volume":"202","author":"K Machida","year":"2020","unstructured":"Machida K, Aw M, Salter BMA et al (2020) The role of the TL1A\/DR3 axis in the activation of group 2 innate lymphoid cells in subjects with eosinophilic asthma. Am J Respir Crit Care Med 202:1105\u20131114. https:\/\/doi.org\/10.1164\/rccm.201909-1722OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9152_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.immuni.2018.10.014","volume":"49","author":"JG Castellanos","year":"2018","unstructured":"Castellanos JG, Woo V, Viladomiu M et al (2018) Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis. Immunity 49:1077\u20131089e5. https:\/\/doi.org\/10.1016\/j.immuni.2018.10.014","journal-title":"Immunity"},{"key":"9152_CR29","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/eji.201445213","volume":"45","author":"Y-O Ahn","year":"2015","unstructured":"Ahn Y-O, Weeres MA, Neulen M-L et al (2015) Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. Eur J Immunol 45:2335\u20132342. https:\/\/doi.org\/10.1002\/eji.201445213","journal-title":"Eur J Immunol"},{"key":"9152_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ibd\/izy351","volume":"25","author":"P Tougaard","year":"2019","unstructured":"Tougaard P, Martinsen LO, Zachariassen LF et al (2019) TL1A aggravates cytokine-induced acute gut inflammation and potentiates infiltration of intraepithelial natural killer cells in mice. Inflamm Bowel Dis 25:510\u2013523. https:\/\/doi.org\/10.1093\/ibd\/izy351","journal-title":"Inflamm Bowel Dis"},{"key":"9152_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales C (2018) Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol 9:113. https:\/\/doi.org\/10.3389\/fphys.2018.00113","journal-title":"Front Physiol"},{"key":"9152_CR32","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/art.38770","volume":"66","author":"ECY Wang","year":"2014","unstructured":"Wang ECY, Newton Z, Hayward OA et al (2014) Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis Rheumatol 66:2762\u20132772. https:\/\/doi.org\/10.1002\/art.38770","journal-title":"Arthritis Rheumatol"},{"key":"9152_CR33","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/eji.201444528","volume":"45","author":"P Tougaard","year":"2015","unstructured":"Tougaard P, Skov S, Pedersen AE et al (2015) TL1A regulates TCR\u03b3\u03b4+ intraepithelial lymphocytes and gut microbial composition. Eur J Immunol 45:865\u2013875. https:\/\/doi.org\/10.1002\/eji.201444528","journal-title":"Eur J Immunol"},{"key":"9152_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A et al (2023) T cells in health and disease. Signal Transduct Target Ther 8:235. https:\/\/doi.org\/10.1038\/s41392-023-01471-y","journal-title":"Signal Transduct Target Ther"},{"key":"9152_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156540","volume":"176","author":"N Liman","year":"2024","unstructured":"Liman N, Lanasa D, Meylan F, Park J-H (2024) The ever-expanding role of cytokine receptor DR3 in T cells. Cytokine 176:156540. https:\/\/doi.org\/10.1016\/j.cyto.2024.156540","journal-title":"Cytokine"},{"key":"9152_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1084\/jem.20071364","volume":"205","author":"BP Pappu","year":"2008","unstructured":"Pappu BP, Borodovsky A, Zheng TS et al (2008) TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 205:1049\u20131062. https:\/\/doi.org\/10.1084\/jem.20071364","journal-title":"J Exp Med"},{"key":"9152_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1053\/j.gastro.2025.03.035","volume":"169","author":"P Menghini","year":"2025","unstructured":"Menghini P, Butt\u00f3 LF, Gomez-Nguyen A et al (2025) Tumor Necrosis Factor-Like Ligand 1A\/Death Receptor 3 Signaling Regulates the Generation of Pathogenic T Helper 9 Cells in Experimental Crohn\u2019s Disease. Gastroenterology 169:892\u2013908. https:\/\/doi.org\/10.1053\/j.gastro.2025.03.035","journal-title":"Gastroenterology"},{"key":"9152_CR38","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.4049\/jimmunol.1301475","volume":"191","author":"X Wang","year":"2013","unstructured":"Wang X, Hu Y, Charpentier T et al (2013) TNF-like Ligand 1A (TL1A) Gene Knockout Leads to Ameliorated Collagen-Induced Arthritis in Mice: Implication of TL1A in Humoral Immune Responses. J Immunol 191:5420\u20135429. https:\/\/doi.org\/10.4049\/jimmunol.1301475","journal-title":"J Immunol"},{"key":"9152_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060136","volume":"8","author":"C Cavallini","year":"2013","unstructured":"Cavallini C, Lovato O, Bertolaso A et al (2013) The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. PLoS One 8:e60136. https:\/\/doi.org\/10.1371\/journal.pone.0060136","journal-title":"PLoS One"},{"key":"9152_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/intimm\/dxaf015","volume":"37","author":"T Ito","year":"2025","unstructured":"Ito T, Kayama H (2025) Roles of fibroblasts in the pathogenesis of inflammatory bowel diseases and IBD-associated fibrosis. Int Immunol 37:379\u2013392. https:\/\/doi.org\/10.1093\/intimm\/dxaf015","journal-title":"Int Immunol"},{"key":"9152_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75168-5","volume":"10","author":"N Jacob","year":"2020","unstructured":"Jacob N, Kumagai K, Abraham JP et al (2020) Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo. Sci Rep 10:18189. https:\/\/doi.org\/10.1038\/s41598-020-75168-5","journal-title":"Sci Rep"},{"key":"9152_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11596-024-2875-1","volume":"44","author":"J Song","year":"2024","unstructured":"Song J, Sun D, Li C et al (2024) TL1A promotes fibrogenesis in colonic fibroblasts via the TGF-\u03b21\/Smad3 signaling pathway. Curr Med Sci 44:519\u2013528. https:\/\/doi.org\/10.1007\/s11596-024-2875-1","journal-title":"Curr Med Sci"},{"key":"9152_CR43","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41385-018-0055-y","volume":"11","author":"N Jacob","year":"2018","unstructured":"Jacob N, Jacobs JP, Kumagai K et al (2018) Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome. Mucosal Immunol 11:1466\u20131476. https:\/\/doi.org\/10.1038\/s41385-018-0055-y","journal-title":"Mucosal Immunol"},{"key":"9152_CR44","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.medj.2024.03.010","volume":"5","author":"V Solitano","year":"2024","unstructured":"Solitano V, Jairath V, Ungaro F et al (2024) TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis. Med 5:386\u2013400. https:\/\/doi.org\/10.1016\/j.medj.2024.03.010","journal-title":"Med"},{"key":"9152_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/928461","volume":"2014","author":"J G\u00e1lvez","year":"2014","unstructured":"G\u00e1lvez J (2014) Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm 2014:928461. https:\/\/doi.org\/10.1155\/2014\/928461","journal-title":"ISRN Inflamm"},{"key":"9152_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","volume":"16","author":"SH Lee","year":"2018","unstructured":"Lee SH, Kwon JE, Cho M-L (2018) Immunological pathogenesis of inflammatory bowel disease. Intest Res 16:26\u201342. https:\/\/doi.org\/10.5217\/ir.2018.16.1.26","journal-title":"Intest Res"},{"key":"9152_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135858","volume":"10","author":"S-Y Lee","year":"2015","unstructured":"Lee S-Y, Lee SH, Yang E-J et al (2015) Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17\/Treg balance. PLoS One 10:e0135858. https:\/\/doi.org\/10.1371\/journal.pone.0135858","journal-title":"PLoS One"},{"key":"9152_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/sj.cr.7310009","volume":"16","author":"D Shi","year":"2006","unstructured":"Shi D, Das J, Das G (2006) Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Res 16:70\u201374. https:\/\/doi.org\/10.1038\/sj.cr.7310009","journal-title":"Cell Res"},{"key":"9152_CR49","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/MIB.0000000000000343","volume":"21","author":"D Geem","year":"2015","unstructured":"Geem D, Harusato A, Flannigan K, Denning TL (2015) Harnessing regulatory T cells for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 21:1409\u20131418. https:\/\/doi.org\/10.1097\/MIB.0000000000000343","journal-title":"Inflamm Bowel Dis"},{"key":"9152_CR50","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","volume":"20","author":"MF Neurath","year":"2019","unstructured":"Neurath MF (2019) Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 20:970\u2013979. https:\/\/doi.org\/10.1038\/s41590-019-0415-0","journal-title":"Nat Immunol"},{"key":"9152_CR51","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","volume":"15","author":"M Cutolo","year":"2019","unstructured":"Cutolo M, Soldano S, Smith V (2019) Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol 15:753\u2013764. https:\/\/doi.org\/10.1080\/1744666X.2019.1614915","journal-title":"Expert Rev Clin Immunol"},{"key":"9152_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103185","volume":"21","author":"W Jin","year":"2022","unstructured":"Jin W, Zheng Y, Zhu P (2022) T cell abnormalities in systemic sclerosis. Autoimmun Rev 21:103185. https:\/\/doi.org\/10.1016\/j.autrev.2022.103185","journal-title":"Autoimmun Rev"},{"key":"9152_CR53","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/immuno2030034","volume":"2","author":"LI Sakkas","year":"2022","unstructured":"Sakkas LI, Bogdanos DP (2022) The role of T cells in systemic sclerosis: an update. Immun 2:534\u2013547. https:\/\/doi.org\/10.3390\/immuno2030034","journal-title":"Immun"},{"key":"9152_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.826839","volume":"13","author":"B Dai","year":"2022","unstructured":"Dai B, Ding L, Zhao L et al (2022) Contributions of immune cells and stromal cells to the pathogenesis of systemic sclerosis: recent insights. Front Pharmacol 13:826839. https:\/\/doi.org\/10.3389\/fphar.2022.826839","journal-title":"Front Pharmacol"},{"key":"9152_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/ar4230","volume":"15","author":"AJ Gilbane","year":"2013","unstructured":"Gilbane AJ, Denton CP, Holmes AM (2013) Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 15:215. https:\/\/doi.org\/10.1186\/ar4230","journal-title":"Arthritis Res Ther"},{"key":"9152_CR56","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s10067-017-3612-y","volume":"36","author":"W Xu","year":"2017","unstructured":"Xu W, Su L, Qing P et al (2017) Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis. Clin Rheumatol 36:1317\u20131324. https:\/\/doi.org\/10.1007\/s10067-017-3612-y","journal-title":"Clin Rheumatol"},{"key":"9152_CR57","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jimmun\/vkaf002","volume":"214","author":"H Steele","year":"2025","unstructured":"Steele H, Willicut A, Dell G et al (2025) Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis. J Immunol 214:808\u2013817. https:\/\/doi.org\/10.1093\/jimmun\/vkaf002","journal-title":"J Immunol"},{"issue":"9","key":"9152_CR58","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.4049\/jimmunol.2000665","volume":"205","author":"R Herro","year":"2020","unstructured":"Herro R, Miki H, Sethi GS et al (2020) TL1A promotes lung tissue fibrosis and airway remodeling. J Immunol 205(9):2414\u20132422. https:\/\/doi.org\/10.4049\/jimmunol.2000665","journal-title":"J Immunol"},{"key":"9152_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1183\/09059180.00003214","volume":"24","author":"G Bagnato","year":"2015","unstructured":"Bagnato G, Harari S (2015) Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 24:102\u2013114. https:\/\/doi.org\/10.1183\/09059180.00003214","journal-title":"Eur Respir Rev"},{"key":"9152_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1089\/ars.2007.1897","volume":"10","author":"BD Bringardner","year":"2008","unstructured":"Bringardner BD, Baran CP, Eubank TD, Marsh CB (2008) The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 10:287\u2013301. https:\/\/doi.org\/10.1089\/ars.2007.1897","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"9152_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12948-015-0022-z","volume":"13","author":"M Facco","year":"2015","unstructured":"Facco M, Cabrelle A, Calabrese F et al (2015) TL1A\/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis. Clin Mol Allergy CMA 13:16. https:\/\/doi.org\/10.1186\/s12948-015-0022-z","journal-title":"Clin Mol Allergy CMA"},{"key":"9152_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","volume":"147","author":"P Heukels","year":"2019","unstructured":"Heukels P, Moor CC, Von Der Th\u00fcsen JH et al (2019) Inflammation and immunity in IPF pathogenesis and treatment. Respir Med 147:79\u201391. https:\/\/doi.org\/10.1016\/j.rmed.2018.12.015","journal-title":"Respir Med"},{"key":"9152_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GBE et al (2024) Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol 190:149\u2013162. https:\/\/doi.org\/10.1093\/bjd\/ljad345","journal-title":"Br J Dermatol"},{"issue":"5","key":"9152_CR64","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamadermatol.2018.0141","volume":"154","author":"R Thomi","year":"2018","unstructured":"Thomi R, Cazzaniga S, Seyed Jafari SM et al (2018) Association of hidradenitis suppurativa with T helper 1\/T helper 17 phenotypes: a semantic map analysis. JAMA Dermatol 154:592. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0141","journal-title":"JAMA Dermatol"},{"key":"9152_CR65","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjd.19556","volume":"183","author":"K Wolk","year":"2020","unstructured":"Wolk K, Join-Lambert O, Sabat R (2020) Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 183:999\u20131010. https:\/\/doi.org\/10.1111\/bjd.19556","journal-title":"Br J Dermatol"},{"key":"9152_CR66","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4103\/ijd.ijd_594_22","volume":"68","author":"SS Verma","year":"2023","unstructured":"Verma SS, Sharma K, Chhabra S (2023) Pathogenesis of hidradenitis suppurativa: an immunological perspective. Indian J Dermatol 68:296\u2013300. https:\/\/doi.org\/10.4103\/ijd.ijd_594_22","journal-title":"Indian J Dermatol"},{"key":"9152_CR67","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00011-017-1074-y","volume":"66","author":"A Shah","year":"2017","unstructured":"Shah A, Alhusayen R, Amini-Nik S (2017) The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res 66:931\u2013945. https:\/\/doi.org\/10.1007\/s00011-017-1074-y","journal-title":"Inflamm Res"},{"key":"9152_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281688","volume":"18","author":"A Petrasca","year":"2023","unstructured":"Petrasca A, Hambly R, Molloy O et al (2023) Innate lymphoid cell (ILC) subsets are enriched in the skin of patients with hidradenitis suppurativa. PLoS One 18:e0281688. https:\/\/doi.org\/10.1371\/journal.pone.0281688","journal-title":"PLoS One"},{"key":"9152_CR69","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139932","volume":"5","author":"MM Lowe","year":"2020","unstructured":"Lowe MM, Naik HB, Clancy S et al (2020) Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy. JCI Insight 5:e139932. https:\/\/doi.org\/10.1172\/jci.insight.139932","journal-title":"JCI Insight"},{"key":"9152_CR70","doi-asserted-by":"publisher","unstructured":"Zouboulis CC (2025) Hidradenitis suppurativa preclinical studies: models and results. Exp Dermatol 34(Suppl 1):e70089. https:\/\/doi.org\/10.1111\/exd.70089","DOI":"10.1111\/exd.70089"},{"key":"9152_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.09.184","volume":"145","author":"H Llewellyn","year":"2025","unstructured":"Llewellyn H, Thoi L, Bogle R et al (2025) 169 The TL1A-DR3 axis coordinates antigen presenting cell and IL17\u2009+\u2009T cell crosstalk in HS. J Invest Dermatol 145:e59. https:\/\/doi.org\/10.1016\/j.jid.2025.09.184","journal-title":"J Invest Dermatol"},{"key":"9152_CR72","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.biopha.2018.01.108","volume":"100","author":"A Rezaiemanesh","year":"2018","unstructured":"Rezaiemanesh A, Abdolmaleki M, Abdolmohammadi K et al (2018) Immune cells involved in the pathogenesis of ankylosing spondylitis. Biomed Pharmacother 100:198\u2013204. https:\/\/doi.org\/10.1016\/j.biopha.2018.01.108","journal-title":"Biomed Pharmacother"},{"key":"9152_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0057-8","volume":"7","author":"W Zhu","year":"2019","unstructured":"Zhu W, He X, Cheng K et al (2019) Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res 7:22. https:\/\/doi.org\/10.1038\/s41413-019-0057-8","journal-title":"Bone Res"},{"key":"9152_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03266-0","volume":"26","author":"Y Fei","year":"2024","unstructured":"Fei Y, Yu H, Wu Y, Gong S (2024) The causal relationship between immune cells and ankylosing spondylitis: a bidirectional Mendelian randomization study. Arthritis Res Ther 26:24. https:\/\/doi.org\/10.1186\/s13075-024-03266-0","journal-title":"Arthritis Res Ther"},{"key":"9152_CR75","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60:1647\u20131656. https:\/\/doi.org\/10.1002\/art.24568","journal-title":"Arthritis Rheum"},{"key":"9152_CR76","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/rheumatology\/kes316","volume":"52","author":"M Konsta","year":"2013","unstructured":"Konsta M, Bamias G, Tektonidou MG et al (2013) Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. Rheumatology 52:448\u2013451. https:\/\/doi.org\/10.1093\/rheumatology\/kes316","journal-title":"Rheumatology"},{"key":"9152_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02198-9","volume":"22","author":"Y-J Song","year":"2020","unstructured":"Song Y-J, Choi I, Meylan F et al (2020) Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF. Arthritis Res Ther 22:106. https:\/\/doi.org\/10.1186\/s13075-020-02198-9","journal-title":"Arthritis Res Ther"},{"key":"9152_CR78","doi-asserted-by":"publisher","unstructured":"Collins FL, Williams JO, Bloom AC et al (2015) Death receptor 3 (TNFRSF25) increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA\/1 mice. Journal of Immunology Research 2015:901679. https:\/\/doi.org\/10.1155\/2015\/901679","DOI":"10.1155\/2015\/901679"},{"key":"9152_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100161","volume":"7","author":"H-Y Yap","year":"2018","unstructured":"Yap H-Y, Tee S-Y, Wong M-T et al (2018) Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells 7:161. https:\/\/doi.org\/10.3390\/cells7100161","journal-title":"Cells"},{"key":"9152_CR80","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrrheum.2009.263","volume":"6","author":"J Bayry","year":"2010","unstructured":"Bayry J (2010) Tl1a in the inflammatory network in autoimmune diseases. Nat Rev Rheumatol 6:67\u201368. https:\/\/doi.org\/10.1038\/nrrheum.2009.263","journal-title":"Nat Rev Rheumatol"},{"key":"9152_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020905","volume":"23","author":"S Jang","year":"2022","unstructured":"Jang S, Kwon E-J, Lee JJ (2022) Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci 23:905. https:\/\/doi.org\/10.3390\/ijms23020905","journal-title":"Int J Mol Sci"},{"key":"9152_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.509","volume":"5","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhang Y, Liu X (2024) Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm 5:e509. https:\/\/doi.org\/10.1002\/mco2.509","journal-title":"MedComm"},{"key":"9152_CR83","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.4049\/jimmunol.0802645","volume":"183","author":"J Zhang","year":"2009","unstructured":"Zhang J, Wang X, Fahmi H et al (2009) Role of TL1A in the Pathogenesis of Rheumatoid Arthritis. J Immunol 183:5350\u20135357. https:\/\/doi.org\/10.4049\/jimmunol.0802645","journal-title":"J Immunol"},{"key":"9152_CR84","doi-asserted-by":"publisher","first-page":"7325","DOI":"10.4049\/jimmunol.178.11.7325","volume":"178","author":"MA Cassatella","year":"2007","unstructured":"Cassatella MA, Da Silva GP, Tinazzi I et al (2007) Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 178:7325\u20137333. https:\/\/doi.org\/10.4049\/jimmunol.178.11.7325","journal-title":"J Immunol"},{"key":"9152_CR85","doi-asserted-by":"publisher","unstructured":"Danese S, Allegretti JR, Schreiber S et al (2025) Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol S2468125325001293. https:\/\/doi.org\/10.1016\/S2468-1253(25)00129-3","DOI":"10.1016\/S2468-1253(25)00129-3"},{"key":"9152_CR86","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/bcp.14187","volume":"86","author":"C Banfield","year":"2020","unstructured":"Banfield C, Rudin D, Bhattacharya I et al (2020) First-in\u2010human, randomized dose\u2010escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF\u201006480605 in healthy subjects. Br J Clin Pharmacol 86:812\u2013824. https:\/\/doi.org\/10.1111\/bcp.14187","journal-title":"Br J Clin Pharmacol"},{"key":"9152_CR87","doi-asserted-by":"publisher","first-page":"e70187","DOI":"10.1111\/cts.70187","volume":"18","author":"K Fukuhara","year":"2025","unstructured":"Fukuhara K, Neelakantan S, Furihata K et al (2025) Japanese Phase 1 Study for Global Development of Anti- TL1A Antibody PF \u201006480605: A Randomized, Placebo\u2010Controlled, Single\u2010Ascending Dose Study. Clin Transl Sci 18:e70187. https:\/\/doi.org\/10.1111\/cts.70187","journal-title":"Clin Transl Sci"},{"key":"9152_CR88","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","volume":"19","author":"S Danese","year":"2021","unstructured":"Danese S, Klopocka M, Scherl EJ et al (2021) Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study. Clin Gastroenterol Hepatol 19:2324-2332e.e6. https:\/\/doi.org\/10.1016\/j.cgh.2021.06.011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9152_CR89","doi-asserted-by":"publisher","first-page":"587","DOI":"10.5863\/1551-6776-29.6.587","volume":"29","author":"J Jeskey","year":"2024","unstructured":"Jeskey J, Kurien C, Blunk H et al (2024) Atopic dermatitis: a review of diagnosis and treatment. J Pediatr Pharmacol Ther 29:587\u2013603. https:\/\/doi.org\/10.5863\/1551-6776-29.6.587","journal-title":"J Pediatr Pharmacol Ther"},{"key":"9152_CR90","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1201a152","volume":"12","author":"LF Santamaria-Bab\u00ed","year":"2022","unstructured":"Santamaria-Bab\u00ed LF (2022) Atopic dermatitis pathogenesis: lessons from immunology. Dermatol Pract Concept 12:e2022152. https:\/\/doi.org\/10.5826\/dpc.1201a152","journal-title":"Dermatol Pract Concept"},{"key":"9152_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040867","volume":"12","author":"M Krupka-Olek","year":"2024","unstructured":"Krupka-Olek M, Bo\u017cek A, Aebisher D et al (2024) Potential aspects of the use of cytokines in atopic dermatitis. Biomedicines 12:867. https:\/\/doi.org\/10.3390\/biomedicines12040867","journal-title":"Biomedicines"},{"key":"9152_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70029","volume":"5","author":"C Yue","year":"2024","unstructured":"Yue C, Zhou H, Wang X et al (2024) Atopic dermatitis: pathogenesis and therapeutic intervention. MedComm 5:e70029. https:\/\/doi.org\/10.1002\/mco2.70029","journal-title":"MedComm"},{"key":"9152_CR93","doi-asserted-by":"publisher","DOI":"10.1159\/000539534","author":"Y Pan","year":"2024","unstructured":"Pan Y, Wang Y, Xu M et al (2024) The roles of innate immune cells in atopic dermatitis. J Innate Immun. https:\/\/doi.org\/10.1159\/000539534","journal-title":"J Innate Immun"},{"key":"9152_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031813","volume":"24","author":"T Hisamoto","year":"2023","unstructured":"Hisamoto T, Suga H, Yoshizaki-Ogawa A et al (2023) Increased serum levels of tumor necrosis factor-like ligand 1A in atopic dermatitis. Int J Mol Sci 24:1813. https:\/\/doi.org\/10.3390\/ijms24031813","journal-title":"Int J Mol Sci"},{"key":"9152_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01307-5","author":"Y He","year":"2025","unstructured":"He Y, Chen Y, Qian S et al (2025) Immunopathogenic mechanisms and immunoregulatory therapies in MASLD. Cell Mol Immunol. https:\/\/doi.org\/10.1038\/s41423-025-01307-5","journal-title":"Cell Mol Immunol"},{"key":"9152_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000518407","volume":"14","author":"M Nati","year":"2022","unstructured":"Nati M, Chung K-J, Chavakis T (2022) The role of innate immune cells in nonalcoholic fatty liver disease. J Innate Immun 14:31\u201341. https:\/\/doi.org\/10.1159\/000518407","journal-title":"J Innate Immun"},{"key":"9152_CR97","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/cmi.2011.53","volume":"9","author":"R Xu","year":"2012","unstructured":"Xu R, Zhang Z, Wang F-S (2012) Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol 9:296\u2013301. https:\/\/doi.org\/10.1038\/cmi.2011.53","journal-title":"Cell Mol Immunol"},{"key":"9152_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257596","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, Lang R (2023) Macrophage metabolism in nonalcoholic fatty liver disease. Front Immunol 14:1257596. https:\/\/doi.org\/10.3389\/fimmu.2023.1257596","journal-title":"Front Immunol"},{"key":"9152_CR99","doi-asserted-by":"publisher","unstructured":"Guo J, Luo Y, Yin F et al (2019) Overexpression of tumor necrosis factor-like ligand 1 A in myeloid cells aggravates liver fibrosis in mice. J Immunol Res 2019:7657294. https:\/\/doi.org\/10.1155\/2019\/7657294","DOI":"10.1155\/2019\/7657294"},{"key":"9152_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goae089","volume":"12","author":"T Mori","year":"2024","unstructured":"Mori T, Yoshio S, Kakazu E, Kanto T (2024) Active role of the immune system in metabolic dysfunction-associated steatotic liver disease. Gastroenterol Rep 12:goae089. https:\/\/doi.org\/10.1093\/gastro\/goae089","journal-title":"Gastroenterol Rep"},{"key":"9152_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1445634","volume":"15","author":"M Cebi","year":"2024","unstructured":"Cebi M, Yilmaz Y (2024) Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes. Front Immunol 15:1445634. https:\/\/doi.org\/10.3389\/fimmu.2024.1445634","journal-title":"Front Immunol"},{"key":"9152_CR102","doi-asserted-by":"publisher","first-page":"i77","DOI":"10.1093\/ecco-jcc\/jjae190.0039A","volume":"19","author":"V Jairath","year":"2025","unstructured":"Jairath V, Kierkus J, Duvall GA et al (2025) OP40 duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn\u2019s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD). J Crohns Colitis 19:i77\u2013i78. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0039A","journal-title":"J Crohns Colitis"},{"key":"9152_CR103","doi-asserted-by":"publisher","first-page":"i79","DOI":"10.1093\/ecco-jcc\/jjae190.0039B","volume":"19","author":"W Reinisch","year":"2025","unstructured":"Reinisch W, Stepek D, Kempinski R et al (2025) OP41 duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD). J Crohns Colitis 19:i79\u2013i80. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0039B","journal-title":"J Crohns Colitis"},{"key":"9152_CR104","doi-asserted-by":"publisher","first-page":"i1206","DOI":"10.1093\/ecco-jcc\/jjad212.0763","volume":"18","author":"R Balyan","year":"2024","unstructured":"Balyan R, Ghibellini G, Sunzel EM et al (2024) P633 first-in-human pharmacokinetic and safety study of an anti-TL1A antibody, TEV-48574, in healthy volunteers and asthma patients. J Crohns Colitis 18:i1206\u2013i1207. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0763","journal-title":"J Crohns Colitis"},{"key":"9152_CR105","doi-asserted-by":"publisher","first-page":"i1899","DOI":"10.1093\/ecco-jcc\/jjad212.1191","volume":"18","author":"G Raphael","year":"2024","unstructured":"Raphael G, Damera G, Angeles T et al (2024) P1061 TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following 16 weeks of subcutaneous treatment in adults with severe uncontrolled T2-low\/non T2 asthma. J Crohns Colitis 18:i1899\u2013i1899. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.1191","journal-title":"J Crohns Colitis"},{"key":"9152_CR106","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4168\/aair.2022.14.2.233","volume":"14","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang D, Pan Y et al (2022) The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling. Allergy Asthma Immunol Res 14:233\u2013253. https:\/\/doi.org\/10.4168\/aair.2022.14.2.233","journal-title":"Allergy Asthma Immunol Res"},{"key":"9152_CR107","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jaci.2025.02.018","volume":"155","author":"G Varricchi","year":"2025","unstructured":"Varricchi G, Poto R, Criscuolo G et al (2025) TL1A, a novel alarmin in airway, intestinal, and autoimmune disorders. J Allergy Clin Immunol 155:1420\u20131434. https:\/\/doi.org\/10.1016\/j.jaci.2025.02.018","journal-title":"J Allergy Clin Immunol"},{"key":"9152_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692127","volume":"12","author":"H Steele","year":"2021","unstructured":"Steele H, Sachen K, McKnight AJ et al (2021) Targeting TL1A\/DR3 signaling offers a therapeutic advantage to neutralizing IL13\/IL4R\u03b1 in muco-secretory fibrotic disorders. Front Immunol 12:692127. https:\/\/doi.org\/10.3389\/fimmu.2021.692127","journal-title":"Front Immunol"},{"key":"9152_CR109","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","volume":"184","author":"H Hammad","year":"2021","unstructured":"Hammad H, Lambrecht BN (2021) The basic immunology of asthma. Cell 184:1469\u20131485. https:\/\/doi.org\/10.1016\/j.cell.2021.02.016","journal-title":"Cell"},{"key":"9152_CR110","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccm.2018.10.014","volume":"40","author":"RS Peebles","year":"2019","unstructured":"Peebles RS, Aronica MA (2019) Proinflammatory pathways in the pathogenesis of asthma. Clin Chest Med 40:29\u201350. https:\/\/doi.org\/10.1016\/j.ccm.2018.10.014","journal-title":"Clin Chest Med"},{"key":"9152_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.13688","volume":"171","author":"Z Qin","year":"2024","unstructured":"Qin Z, Chen Y, Wang Y et al (2024) Immunometabolism in the pathogenesis of asthma. Immunology 171:1\u201317. https:\/\/doi.org\/10.1111\/imm.13688","journal-title":"Immunology"},{"key":"9152_CR112","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jmb.2008.07.051","volume":"382","author":"PJ Lupardus","year":"2008","unstructured":"Lupardus PJ, Garcia KC (2008) The structure of Interleukin-23 reveals the molecular basis of p40 subunit sharing with IL-12. J Mol Biol 382:931\u2013941. https:\/\/doi.org\/10.1016\/j.jmb.2008.07.051","journal-title":"J Mol Biol"},{"key":"9152_CR113","doi-asserted-by":"publisher","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945. https:\/\/doi.org\/10.1001\/jama.2020.4006","DOI":"10.1001\/jama.2020.4006"},{"key":"9152_CR114","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","volume":"66","author":"I Sieminska","year":"2024","unstructured":"Sieminska I, Pieniawska M, Grzywa TM (2024) The immunology of psoriasis-current concepts in pathogenesis. Clin Rev Allergy Immunol 66:164\u2013191. https:\/\/doi.org\/10.1007\/s12016-024-08991-7","journal-title":"Clin Rev Allergy Immunol"},{"key":"9152_CR115","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/apm.12385","volume":"123","author":"AE Pedersen","year":"2015","unstructured":"Pedersen AE, Schmidt EGW, S\u00f8rensen JF et al (2015) Secretion, blood levels and cutaneous expression of TL 1A in psoriasis patients. APMIS 123:547\u2013555. https:\/\/doi.org\/10.1111\/apm.12385","journal-title":"APMIS"},{"key":"9152_CR116","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00403-019-02030-8","volume":"312","author":"L Li","year":"2020","unstructured":"Li L, Fu L, Zhou P et al (2020) Effects of tumor necrosis factor-like ligand 1A (TL1A) on imiquimod-induced psoriasiform skin inflammation in mice. Arch Dermatol Res 312:481\u2013490. https:\/\/doi.org\/10.1007\/s00403-019-02030-8","journal-title":"Arch Dermatol Res"},{"key":"9152_CR117","doi-asserted-by":"publisher","first-page":"1340467","DOI":"10.3389\/fimmu.2024.1340467","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, Kozai M, Hiraishi M et al (2024) Roles of tumor necrosis factor-like ligand 1A in \u03b3\u03b4T-cell activation and psoriasis pathogenesis. Front Immunol 15:1340467. https:\/\/doi.org\/10.3389\/fimmu.2024.1340467","journal-title":"Front Immunol"},{"key":"9152_CR118","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","volume":"24","author":"J Choi","year":"2012","unstructured":"Choi J, Kim ST, Craft J (2012) The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 24:651\u2013657. https:\/\/doi.org\/10.1016\/j.coi.2012.10.004","journal-title":"Curr Opin Immunol"},{"key":"9152_CR119","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00296-015-3277-2","volume":"35","author":"W-D Xu","year":"2015","unstructured":"Xu W-D, Chen D-J, Li R et al (2015) Elevated plasma levels of TL1A in newly diagnosed systemic lupus erythematosus patients. Rheumatol Int 35:1435\u20131437. https:\/\/doi.org\/10.1007\/s00296-015-3277-2","journal-title":"Rheumatol Int"},{"key":"9152_CR120","doi-asserted-by":"publisher","first-page":"101388","DOI":"10.1016\/j.beem.2020.101388","volume":"34","author":"A Antonelli","year":"2020","unstructured":"Antonelli A, Fallahi P, Elia G et al (2020) Graves\u2019 disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab 34:101388. https:\/\/doi.org\/10.1016\/j.beem.2020.101388","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"9152_CR121","doi-asserted-by":"publisher","first-page":"16432","DOI":"10.3390\/ijms242216432","volume":"24","author":"N Kustrimovic","year":"2023","unstructured":"Kustrimovic N, Gallo D, Piantanida E et al (2023) Regulatory T Cells in the Pathogenesis of Graves\u2019 Disease. Int J Mol Sci 24:16432. https:\/\/doi.org\/10.3390\/ijms242216432","journal-title":"Int J Mol Sci"},{"key":"9152_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101743","volume":"37","author":"Y Wang","year":"2023","unstructured":"Wang Y, Fang S, Zhou H (2023) Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms. Best Pract Res Clin Endocrinol Metab 37:101743. https:\/\/doi.org\/10.1016\/j.beem.2023.101743","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"9152_CR123","doi-asserted-by":"publisher","first-page":"1455025","DOI":"10.3389\/fimmu.2024.1455025","volume":"15","author":"L Hao","year":"2024","unstructured":"Hao L, Yang J, Lian B et al (2024) Study on serum TL1A levels and their correlation with Th17 cells, IL-17 and IL-21 in children with Graves\u2019 disease. Front Immunol 15:1455025. https:\/\/doi.org\/10.3389\/fimmu.2024.1455025","journal-title":"Front Immunol"},{"key":"9152_CR124","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1080\/02713683.2019.1705494","volume":"45","author":"M Zhang","year":"2020","unstructured":"Zhang M, Liu S, Xu J et al (2020) TNFSF15 Polymorphisms are Associated with Graves\u2019 Disease and Graves\u2019 Ophthalmopathy in a Han Chinese Population. Curr Eye Res 45:888\u2013895. https:\/\/doi.org\/10.1080\/02713683.2019.1705494","journal-title":"Curr Eye Res"},{"key":"9152_CR125","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037297","volume":"103","author":"M Haki","year":"2024","unstructured":"Haki M, AL-Biati HA, Al-Tameemi ZS et al (2024) Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore) 103:e37297. https:\/\/doi.org\/10.1097\/MD.0000000000037297","journal-title":"Medicine (Baltimore)"},{"key":"9152_CR126","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ncl.2010.12.009","volume":"29","author":"GF Wu","year":"2011","unstructured":"Wu GF, Alvarez E (2011) The immunopathophysiology of multiple sclerosis. Neurol Clin 29:257\u2013278. https:\/\/doi.org\/10.1016\/j.ncl.2010.12.009","journal-title":"Neurol Clin"},{"key":"9152_CR127","doi-asserted-by":"publisher","first-page":"1540263","DOI":"10.3389\/fimmu.2025.1540263","volume":"16","author":"C Prado","year":"2025","unstructured":"Prado C, Herrada AA, Hevia D et al (2025) Role of innate immune cells in multiple sclerosis. Front Immunol 16:1540263. https:\/\/doi.org\/10.3389\/fimmu.2025.1540263","journal-title":"Front Immunol"},{"key":"9152_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577020","volume":"335","author":"P Basnyat","year":"2019","unstructured":"Basnyat P, Sumelahti M-L, Lehtim\u00e4ki T et al (2019) Gene expression profiles of TNF-like cytokine 1A (TL1A) and its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) in multiple sclerosis. J Neuroimmunol 335:577020. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577020","journal-title":"J Neuroimmunol"},{"key":"9152_CR129","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.molimm.2009.09.017","volume":"47","author":"S-J Chen","year":"2009","unstructured":"Chen S-J, Wang Y-L, Kao J-H et al (2009) Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells. Mol Immunol 47:567\u2013574. https:\/\/doi.org\/10.1016\/j.molimm.2009.09.017","journal-title":"Mol Immunol"},{"key":"9152_CR130","doi-asserted-by":"publisher","first-page":"970789","DOI":"10.1155\/2012\/970789","volume":"2012","author":"S-J Chen","year":"2012","unstructured":"Chen S-J, Wang Y-L, Fan H-C et al (2012) Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol 2012:970789. https:\/\/doi.org\/10.1155\/2012\/970789","journal-title":"Clin Dev Immunol"},{"key":"9152_CR131","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3390\/jcm9041081","volume":"9","author":"R Jain","year":"2020","unstructured":"Jain R, Yadav D, Puranik N et al (2020) Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments. J Clin Med 9:1081. https:\/\/doi.org\/10.3390\/jcm9041081","journal-title":"J Clin Med"},{"key":"9152_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103247","volume":"149","author":"J Miedema","year":"2024","unstructured":"Miedema J, Cinetto F, Smed-S\u00f6rensen A, Spagnolo P (2024) The immunopathogenesis of sarcoidosis. J Autoimmun 149:103247. https:\/\/doi.org\/10.1016\/j.jaut.2024.103247","journal-title":"J Autoimmun"},{"key":"9152_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.991394","volume":"9","author":"L Rizzi","year":"2022","unstructured":"Rizzi L, Sabb\u00e0 C, Suppressa P (2022) Sarcoidosis and autoimmunity: in the depth of a complex relationship. Front Med 9:991394. https:\/\/doi.org\/10.3389\/fmed.2022.991394","journal-title":"Front Med"},{"key":"9152_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112360","volume":"137","author":"C Ma","year":"2024","unstructured":"Ma C, Huang J, Zheng Y et al (2024) Anti-TL1A monoclonal antibody modulates the dysregulation of Th1\/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K\/AKT signaling pathway. Int Immunopharmacol 137:112360. https:\/\/doi.org\/10.1016\/j.intimp.2024.112360","journal-title":"Int Immunopharmacol"},{"key":"9152_CR135","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10238-022-00954-6","volume":"23","author":"X Wu","year":"2023","unstructured":"Wu X, Tao M, Zhu L et al (2023) Pathogenesis and current therapies for non-infectious uveitis. Clin Exp Med 23:1089\u20131106. https:\/\/doi.org\/10.1007\/s10238-022-00954-6","journal-title":"Clin Exp Med"},{"key":"9152_CR136","doi-asserted-by":"publisher","first-page":"1402074","DOI":"10.3389\/fimmu.2024.1402074","volume":"15","author":"J Wu","year":"2024","unstructured":"Wu J, Fang C, Zhou Y et al (2024) Causal role of immune cells in uveitis: Mendelian randomization study. Front Immunol 15:1402074. https:\/\/doi.org\/10.3389\/fimmu.2024.1402074","journal-title":"Front Immunol"},{"key":"9152_CR137","first-page":"3486","volume":"17","author":"T Qin","year":"2011","unstructured":"Qin T (2011) Upregulation of DR3 expression in CD4+ T cells promotes secretion of IL-17 in experimental autoimmune uveitis. Mol Vis 17:3486\u20133493","journal-title":"Mol Vis"},{"issue":"8","key":"9152_CR138","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1167\/iovs.15-16896","volume":"56","author":"H Li","year":"2015","unstructured":"Li H, Hou S, Yu H et al (2015) Association of genetic variations in TNFSF15 with acute anterior uveitis in Chinese Han. Invest Ophthalmol Vis Sci 56:4605. https:\/\/doi.org\/10.1167\/iovs.15-16896","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9152_CR139","doi-asserted-by":"publisher","unstructured":"Richard AC, Tan C, Hawley ET et al (2015) The TNF-family ligand TL1A and its receptor DR3 promote T-cell mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9 producing T cells. The Journal of Immunology 194:3567\u20133582. https:\/\/doi.org\/10.4049\/jimmunol.1401220","DOI":"10.4049\/jimmunol.1401220"},{"key":"9152_CR140","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3109\/09273948.2012.658135","volume":"20","author":"CJ Calder","year":"2012","unstructured":"Calder CJ, Wang ECY (2012) An essential role for death receptor 3 in experimental autoimmune uveoretinitis. Ocul Immunol Inflamm 20:212\u2013214. https:\/\/doi.org\/10.3109\/09273948.2012.658135","journal-title":"Ocul Immunol Inflamm"},{"key":"9152_CR141","doi-asserted-by":"publisher","first-page":"926","DOI":"10.4254\/wjh.v7.i7.926","volume":"7","author":"T Purohit","year":"2015","unstructured":"Purohit T, Cappell MS (2015) Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J Hepatol 7:926\u2013941. https:\/\/doi.org\/10.4254\/wjh.v7.i7.926","journal-title":"World J Hepatol"},{"key":"9152_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-1","volume":"3","author":"T Kumagi","year":"2008","unstructured":"Kumagi T, Heathcote E (2008) Primary biliary cirrhosis. Orphanet J Rare Dis 3:1. https:\/\/doi.org\/10.1186\/1750-1172-3-1","journal-title":"Orphanet J Rare Dis"},{"key":"9152_CR143","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","volume":"64","author":"GJ Webb","year":"2015","unstructured":"Webb GJ, Siminovitch KA, Hirschfield GM (2015) The immunogenetics of primary biliary cirrhosis: a comprehensive review. J Autoimmun 64:42\u201352. https:\/\/doi.org\/10.1016\/j.jaut.2015.07.004","journal-title":"J Autoimmun"},{"key":"9152_CR144","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/liv.12296","volume":"34","author":"Y Aiba","year":"2014","unstructured":"Aiba Y, Harada K, Komori A et al (2014) Systemic and local expression levels of TNF -like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis. Liver Int 34:679\u2013688. https:\/\/doi.org\/10.1111\/liv.12296","journal-title":"Liver Int"},{"key":"9152_CR145","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.CD008794.pub2","volume":"2011","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD008794. https:\/\/doi.org\/10.1002\/14651858.CD008794.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"9152_CR146","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2468-1253(25)00106-2","volume":"10","author":"B Gomersall","year":"2025","unstructured":"Gomersall B (2025) ECCO\u201925. Lancet Gastroenterol Hepatol 10:416. https:\/\/doi.org\/10.1016\/S2468-1253(25)00106-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9152_CR147","doi-asserted-by":"publisher","first-page":"D998","DOI":"10.1093\/nar\/gkae1070","volume":"53","author":"M Cerezo","year":"2025","unstructured":"Cerezo M, Sollis E, Ji Y et al (2025) The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity. Nucleic Acids Res 53:D998\u2013D1005. https:\/\/doi.org\/10.1093\/nar\/gkae1070","journal-title":"Nucleic Acids Res"},{"key":"9152_CR148","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41588-024-01972-8","volume":"56","author":"D Western","year":"2024","unstructured":"Western D, Timsina J, Wang L et al (2024) Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer\u2019s disease. Nat Genet 56:2672\u20132684. https:\/\/doi.org\/10.1038\/s41588-024-01972-8","journal-title":"Nat Genet"},{"key":"9152_CR149","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1101\/gr.9.8.677","volume":"9","author":"ST Sherry","year":"1999","unstructured":"Sherry ST, Ward M, Sirotkin K (1999) Dbsnp-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 9:677\u2013679","journal-title":"Genome Res"},{"key":"9152_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5296","volume":"5","author":"AC Palmer","year":"2014","unstructured":"Palmer AC, Kishony R (2014) Opposing effects of target overexpression reveal drug mechanisms. Nat Commun 5:4296. https:\/\/doi.org\/10.1038\/ncomms5296","journal-title":"Nat Commun"},{"key":"9152_CR151","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/1535-7163.MCT-19-0273","volume":"18","author":"R Roy","year":"2019","unstructured":"Roy R, Winteringham LN, Lassmann T, Forrest ARR (2019) Expression levels of therapeutic targets as indicators of sensitivity to targeted therapeutics. Mol Cancer Ther 18:2480\u20132489. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0273","journal-title":"Mol Cancer Ther"},{"key":"9152_CR152","doi-asserted-by":"publisher","unstructured":"(2024) 2024 CPDD Abstract Booklet. Clin Pharmacol Drug Dev 13:1\u2013168. https:\/\/doi.org\/10.1002\/cpdd.1459","DOI":"10.1002\/cpdd.1459"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09152-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:10:36Z","timestamp":1774721436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09152-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":152,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9152"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09152-8","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.H.O. has served as a speaker, an advisory board member, and a researcher for AbbVie, Galderma, Janssen, and Novartis. She has also been a clinical investigator for La Roche-Posay, Merck Sharpe and Dohme, Pfizer, and Sanofi; and a speaker and\/or an advisory board member for Amgen, Boehringer Ingelheim, Eli Lilly and Takeda. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}